Sean Parker, AP
October 17, 2019 07:00 AM EDTUpdated October 18, 12:41 AM
Financing
Startups
Cell/Gene Tx

Sean Park­er helps cre­ate a CRISPRed cell ther­a­py 2.0 play — and he’s got a high-pro­file set of lead­ers on the team

John Carroll

Editor & Founder

You can rack up one more high-pro­file de­but ef­fort in the wave of ac­tiv­i­ty form­ing around cell ther­a­py 2.0. It’s an­oth­er ap­peal­ing Bay Area …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times